Dossier assessment
Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Dossier assessment
Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
-
Extract of dossier assessment
Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of fibroblast growth factor 23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localized in patients aged 1 year and older
Added benefit not proven
Project details
- Project no.
- A22-88
- Commission
- Commission awarded on 22.08.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed